Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 80

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 80
---
 Vaccines
     
    Whole cell and DNAcancer vaccines
     
    PCT/US2015/018688 (WO 2015/134577)
     
    03/04/2015
     
    Nationalized in CH, DE, DK, EP, FR, GB, HK, IE, NL, NO, SE, US
     
    03/04/2035 
     
    Use CompositionComposition

    US 9,555,088US 9,839,680US 10,391,158US 10,751,400
     
    07/07/2016 01/30/2017 12/11/2017 08/26/2019 
     
     Issued 01/31/2017Issued 12/12/2017Issued 08/27/2019Issued 08/25/2020
     
    03/4/203503/4/203503/4/203503/4/2035
     
    Use

    Cancer Vaccine Comprising mRNA Encoding a M-Like- Protein
     
    Next generation cancer vaccine using mRNA encoding a bacterial antigen to prime anti- cancer immune responses
     
    PCT/US2016/033235 (WO 2016/187407)    US 9,636,388US 10,682,401US 18/060,605
     
     05/19/2016    07/28/201605/01/2017 12/01/2022 
     
    Nationalized inAU, CA, CH,CN, DE, DK, EP, FR, GB, HK, IE, JP, NL, NO, SE, US  Issued 05/02/2017Issued 06/16/2020pending
     
          05/19/203605/19/203605/19/2036
     
       Use CompositionComposition/use

    Modified mRNA for Multicell Transformation
     
    Next generation cancer vaccine using mRNA encoding a bacterial antigen to prime anti- cancer immune responses
     
    PCT/US2021/031204 (WO 2021/226413)
     
    05/7/2021
     
    Nationalized in CN, JP, CA, IN, AU, EP, KR